| Carol A Dean, MD | |
|
22 Bramhall St, Portland, ME 04102-3134 | |
| (207) 662-2526 | |
| Not Available |
| Full Name | Carol A Dean |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 34 Years |
| Location | 22 Bramhall St, Portland, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376615682 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD14202 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Spectrum Healthcare Partners Pa | 7618871245 | 265 |
News Archive
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
Twenty dollars a month might not seem like a lot to pay for health insurance. But for people getting by on $15,000 a year, it's enough to make some drop their coverage - especially if they're healthy, a new study of Medicaid expansion participants in Michigan finds.
Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex Tablets (Pramipexole Dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.
Taking a page from the book of San Francisco radio legend Scoop Nisker, biologists who find themselves dissatisfied with the microbes nature has provided are going out and making some of their own. Members of the fast-growing "synthetic biology" research community are designing and constructing novel organisms and biologically-inspired systems - or redesigning existing organisms and systems - to solve problems that natural systems cannot.
A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).
› Verified 2 days ago
| Entity Name | Spectrum Healthcare Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245252212 PECOS PAC ID: 7618871245 Enrollment ID: O20040127000198 |
News Archive
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
Twenty dollars a month might not seem like a lot to pay for health insurance. But for people getting by on $15,000 a year, it's enough to make some drop their coverage - especially if they're healthy, a new study of Medicaid expansion participants in Michigan finds.
Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex Tablets (Pramipexole Dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.
Taking a page from the book of San Francisco radio legend Scoop Nisker, biologists who find themselves dissatisfied with the microbes nature has provided are going out and making some of their own. Members of the fast-growing "synthetic biology" research community are designing and constructing novel organisms and biologically-inspired systems - or redesigning existing organisms and systems - to solve problems that natural systems cannot.
A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).
› Verified 2 days ago
| Entity Name | Spectrum Healthcare Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245252212 PECOS PAC ID: 7618871245 Enrollment ID: O20040915000845 |
News Archive
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
Twenty dollars a month might not seem like a lot to pay for health insurance. But for people getting by on $15,000 a year, it's enough to make some drop their coverage - especially if they're healthy, a new study of Medicaid expansion participants in Michigan finds.
Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex Tablets (Pramipexole Dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.
Taking a page from the book of San Francisco radio legend Scoop Nisker, biologists who find themselves dissatisfied with the microbes nature has provided are going out and making some of their own. Members of the fast-growing "synthetic biology" research community are designing and constructing novel organisms and biologically-inspired systems - or redesigning existing organisms and systems - to solve problems that natural systems cannot.
A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carol A Dean, MD 324 Gannett Dr Ste 200, South Portland, ME 04106-3266 Ph: (207) 482-7800 | Carol A Dean, MD 22 Bramhall St, Portland, ME 04102-3134 Ph: (207) 662-2526 |
News Archive
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
Twenty dollars a month might not seem like a lot to pay for health insurance. But for people getting by on $15,000 a year, it's enough to make some drop their coverage - especially if they're healthy, a new study of Medicaid expansion participants in Michigan finds.
Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex Tablets (Pramipexole Dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.
Taking a page from the book of San Francisco radio legend Scoop Nisker, biologists who find themselves dissatisfied with the microbes nature has provided are going out and making some of their own. Members of the fast-growing "synthetic biology" research community are designing and constructing novel organisms and biologically-inspired systems - or redesigning existing organisms and systems - to solve problems that natural systems cannot.
A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).
› Verified 2 days ago
David Edward Landry, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2526 | |
Francis Altman, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 144 State St, Anesthesia Department, Portland, ME 04101 Phone: 207-879-3385 | |
Dylan Wingfield, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-478-6024 | |
Dr. Frederick Craig Littlejohn, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1945 Congress St Ste 103, Portland, ME 04102 Phone: 207-835-8116 | |
Christopher James Beeler, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-0111 | |
Charles F Adams, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2526 | |
Jeffrey Morse, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 144 State St, Anesthesia Department, Portland, ME 04101 Phone: 207-879-3385 |